Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Personalized Nutrition
... CAGR of 13.5% over the analysis period 2024-2030. Active Measurement, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$27.5 Billion by the end of the analysis ... Read More
-
Pharmaceutical Membrane Filtration
... at a CAGR of 10.5% over the analysis period 2024-2030. Filters, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$11.7 Billion by the end of the ... Read More
-
Parkinson’s Disease Drugs
... at a CAGR of 6.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$4.6 Billion by the end of the ... Read More
-
Epilepsy Drugs
... CAGR of 3.8% over the analysis period 2024-2030. First Generation, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Healthcare Contract Development and Manufacturing Organization
... reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Contract Manufacturing, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach ... Read More
-
Pharmaceutical Glass Tubing
... at a CAGR of 5.7% over the analysis period 2024-2030. Glass Tubing for Syringes, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$8.1 Billion by the ... Read More
-
Vial Adaptors for Reconstitution Drug
... Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Polycarbonate, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.3 Billion by ... Read More
-
Calcium Channel Blockers
... at a CAGR of 6.1% over the analysis period 2024-2030. Dihydropyridine, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.1 Billion by the end of the ... Read More
-
Sodium Alginate
... CAGR of 5.0% over the analysis period 2024-2030. Stabilizers, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$137.4 Million by the end of the analysis period. ... Read More
-
Oral Solid Dosage Contract Manufacturing
... Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$30.0 Billion by ... Read More
-
Sustainable Pharmaceutical Packaging
... at a CAGR of 15.3% over the analysis period 2024-2030. Plastics, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$127.3 Billion by the end of the ... Read More
-
Orphan Drugs
... CAGR of 12.0% over the analysis period 2024-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$308.5 Billion by the end of the analysis ... Read More
-
Campesterol
... 8.5% over the analysis period 2024-2030. Food Ingredients, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$143.1 Million by the end of the analysis period. Growth ... Read More
-
Pharmaceutical Filtration
... CAGR of 17.2% over the analysis period 2024-2030. Membrane Filters, one of the segments analyzed in the report, is expected to record a 21.2% CAGR and reach US$19.6 Billion by the end of the analysis ... Read More
-
Proanthocyanidins
... 6.2% over the analysis period 2024-2030. Cranberry, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$177.2 Million by the end of the analysis period. Growth in ... Read More
-
Pharmaceutical Chemicals
... CAGR of 4.9% over the analysis period 2024-2030. OTC, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$16.8 Billion by the end of the analysis period. ... Read More
-
Pharmaceutical Hot Melt Extrusion Equipment
... Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Twin Screw Extruders, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$28.0 ... Read More
-
Pharmerging
... 9.7% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in ... Read More
-
Sterile Medical Packaging
... at a CAGR of 7.3% over the analysis period 2024-2030. Plastics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$36.5 Billion by the end of the ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Veterinary Drugs Compounding
... at a CAGR of 7.7% over the analysis period 2024-2030. CNS Agents, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.1 Billion by the end of ... Read More
-
Pharmaceutical Contract Manufacturing
... at a CAGR of 5.2% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$93.8 Billion by the end of the ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis period. ... Read More
-
Ampoules Packaging
... CAGR of 6.2% over the analysis period 2024-2030. Glass, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$5.6 Billion by the end of the analysis period. ... Read More
Research Assistance
